drugset / Trial / NCT01089361

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361

Phase 1/2 Completed 19 enrolled Beth Israel Deaconess Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce morbidity and mortality.

Timeline

Start
2009-12
Primary completion
2010-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.1 mg/kg